In this non-comparative trial, patients with BRAFV600-mutant resectable melanoma received either pembrolizumab alone, a sequential combination of pembrolizumab, dabrafenib and trametinib, or a concurrent combination thereof, showing encouraging clinical response rates in the concurrent therapy arm and awaiting longer follow-up.
- Georgina V. Long
- Matteo S. Carlino
- Alexander M. Menzies
